Bloomberg has cited recent data that shows deadly fungi including Candida Auris have spread globally since COVID-19.
The climate change is allowing many illness-causing bacteria to adjust to higher temperatures. This makes them a more formidable threat to the natural body defenses that operate around 37oC.
Investors should take a strategic position in firms that can play an important role in battling this rising health risk.
These are two of the best pharmaceutical companies to buy amid this spike in disease-causing fungal growth.
Gilead Sciences Inc (NASDAQ: GILD)
Gilead, a company widely known for developing antiviral drugs and antifungal medicines, is also heavily involved with Gilead.
AmBisome is one of the most effective antifungal medications.
Due to the company’s history in combating such threats, Gilead is a great pick.
Gilead, for example, was the first to introduce Veklury as an antiviral drug to combat COVID-19, a deadly respiratory disease, in 2020.
Gilead invests billions of dollars each year into research and development, indicating it has the resources necessary to develop its antifungal treatment pipeline and combat the growing threat of deadly fungal epidemics.
Redburn Atlantic, an investment firm, has set a current price target for Gilead at $123 per share. This suggests a possible upside of over 35% from the current level.
The stock also offers an impressive dividend yield of 3.40 %, which makes it a great addition to any investment portfolio. Crispus Nyaga, our market analyst, is bullish about GILD.
Merck & Co Inc. (NYSE: MRK).
Merck, another US-based giant in the pharmaceutical industry with an extensive presence of antifungal treatment including Cancidas.
To maintain its competitive advantage, the company heavily invests in new and improved drugs, especially for fungal infections.
Merck, however, has seen its stock fall by over 20% during the last four months. This makes it a more appealing investment in terms of value.
Merck’s worldwide sales reached $60.1 billion last year, but the company expects this number to increase between $63.6 and $64.1 in 2024. This shows management confidence that growth will continue.
Wall Street has a consensus rating of “overweight”. Analysts project an average target price of $133. This represents a 30% increase from the current level.
Merck is a good investment for income-generating investors. It offers a 3.02% dividend yield, which makes it attractive for those looking to generate passive income in the face of the economic downturn that many predict will hit the US economy by 2025.
The ICD published the article Top 2 Pharma Stocks to Buy amid Surge in Deadly Fungi.
This site is for entertainment only. Click here to read more
